What does GEASSOCIEERDE APOTHEEK MARKGRAVE do?

GEASSOCIEERDE APOTHEEK MARKGRAVE is a pharmacy in Antwerpen. Private Limited, started on 21 December 2007, 1 establishment.

What is the address of GEASSOCIEERDE APOTHEEK MARKGRAVE?

The registered office of GEASSOCIEERDE APOTHEEK MARKGRAVE is located at Markgravelei 32, 2018 Antwerpen.

Is GEASSOCIEERDE APOTHEEK MARKGRAVE still active?

Yes. According to the CBE (19 September 2026) GEASSOCIEERDE APOTHEEK MARKGRAVE is active, legal situation “Normale toestand”, started on 21 December 2007.

Is GEASSOCIEERDE APOTHEEK MARKGRAVE registered on Peppol?

Yes, GEASSOCIEERDE APOTHEEK MARKGRAVE is registered on the Peppol network with ID 0208:0894394240.

What is the enterprise number of GEASSOCIEERDE APOTHEEK MARKGRAVE?

The enterprise number of GEASSOCIEERDE APOTHEEK MARKGRAVE is BE0894394240.

When was GEASSOCIEERDE APOTHEEK MARKGRAVE founded?

GEASSOCIEERDE APOTHEEK MARKGRAVE was founded on 21 December 2007.

Who are the directors of GEASSOCIEERDE APOTHEEK MARKGRAVE?

According to the 2025 annual accounts, the directors of GEASSOCIEERDE APOTHEEK MARKGRAVE are: A. Pirlot, J. Mannaerts.

Is GEASSOCIEERDE APOTHEEK MARKGRAVE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 2007; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did GEASSOCIEERDE APOTHEEK MARKGRAVE make in 2025?

GEASSOCIEERDE APOTHEEK MARKGRAVE recorded a loss after taxes of € 4,387 in financial year 2025.

What is the revenue of GEASSOCIEERDE APOTHEEK MARKGRAVE?

As a small company, GEASSOCIEERDE APOTHEEK MARKGRAVE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 170,360.

How much does an employee at GEASSOCIEERDE APOTHEEK MARKGRAVE earn?

The average wage cost per full-time employee at GEASSOCIEERDE APOTHEEK MARKGRAVE was € 56,700 in 2025: staff costs of € 119,039 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does GEASSOCIEERDE APOTHEEK MARKGRAVE have?

According to the 2025 annual accounts, GEASSOCIEERDE APOTHEEK MARKGRAVE has 2.1 full-time equivalents (FTE).

GEASSOCIEERDE APOTHEEK MARKGRAVE (Private Limited)

Dossier GEASSOCIEERDE APOTHEEK MARKGRAVE, printed on 19 September 2026 from databakkes.be/en/0894394240/geassocieerde-apotheek-markgrave. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 16 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

GEASSOCIEERDE APOTHEEK MARKGRAVE from Antwerpen, company number BE0894394240, closed financial year 2025 with a result of € -4,387 after tax. For that financial year GEASSOCIEERDE APOTHEEK MARKGRAVE recorded a gross margin of € 170,360 and equity of € 138,291. Compared with financial year 2024, the result moved from € 45,229 to € -4,387. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What it is worth Healthy

€ 138,291

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -4,387

▼ still € 45,229 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 18,863

▲ 42% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 117,291.

People and assets in 2025

Full-time equivalents

2.1

▼ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 119,039

▼ 16% vs 2024

€ 56,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,904

▼ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 662,888

▼ 11% vs 2024

€ 84,666 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 206,778

▲ 18% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 19,339

▼ 3% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 256,130 Gross margin 2022: € 256,130 First fiscal year in the series	€ 265,784 Gross margin 2023: € 265,784 ▲ 4% vs 2022 (€ 256,130) Favourable step	€ 232,656 Gross margin 2024: € 232,656 ▼ 12% vs 2023 (€ 265,784) Unfavourable step	€ 170,360 Gross margin 2025: € 170,360 ▼ 27% vs 2024 (€ 232,656) Unfavourable step	▼ 27%
Profit after taxes	€ 65,962 Profit after taxes 2022: € 65,962 First fiscal year in the series	€ 44,196 Profit after taxes 2023: € 44,196 ▼ 33% vs 2022 (€ 65,962) Unfavourable step	€ 45,229 Profit after taxes 2024: € 45,229 ▲ 2% vs 2023 (€ 44,196) Favourable step	€ -4,387 Profit after taxes 2025: € -4,387 ▼ € 49,616 vs 2024 (€ 45,229) Unfavourable step	▼ € 49,616
Equity	€ 142,253 Equity 2022: € 142,253 First fiscal year in the series	€ 142,448 Equity 2023: € 142,448 Unchanged (€ 142,253) Favourable step	€ 142,678 Equity 2024: € 142,678 Unchanged (€ 142,448) Favourable step	€ 138,291 Equity 2025: € 138,291 ▼ 3% vs 2024 (€ 142,678) Unfavourable step	▼ 3%
Total debts	€ 1,407,557 Total debts 2022: € 1,407,557 First fiscal year in the series	€ 1,457,184 Total debts 2023: € 1,457,184 ▲ 4% vs 2022 (€ 1,407,557) Unfavourable step	€ 1,403,343 Total debts 2024: € 1,403,343 ▼ 4% vs 2023 (€ 1,457,184) Favourable step	€ 1,423,109 Total debts 2025: € 1,423,109 ▲ 1% vs 2024 (€ 1,403,343) Unfavourable step	▲ 1%
Cash	€ 38,290 Cash 2022: € 38,290 First fiscal year in the series	€ 60,337 Cash 2023: € 60,337 ▲ 58% vs 2022 (€ 38,290) Favourable step	€ 13,300 Cash 2024: € 13,300 ▼ 78% vs 2023 (€ 60,337) Unfavourable step	€ 18,863 Cash 2025: € 18,863 ▲ 42% vs 2024 (€ 13,300) Favourable step	▲ 42%
Retained profit	€ 121,253 Retained profit 2022: € 121,253 First fiscal year in the series	€ 121,448 Retained profit 2023: € 121,448 Unchanged (€ 121,253) Favourable step	€ 121,678 Retained profit 2024: € 121,678 Unchanged (€ 121,448) Favourable step	€ 117,291 Retained profit 2025: € 117,291 ▼ 4% vs 2024 (€ 121,678) Unfavourable step	▼ 4%
Dividend	€ 65,000 Dividend 2022: € 65,000 First fiscal year in the series	€ 44,000 Dividend 2023: € 44,000 ▼ 32% vs 2022 (€ 65,000) Unchanged	€ 45,000 Dividend 2024: € 45,000 ▲ 2% vs 2023 (€ 44,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 45,000) Unchanged	▼ 100%
Bank debt	€ 893,850 Bank debt 2022: € 893,850 First fiscal year in the series	€ 818,477 Bank debt 2023: € 818,477 ▼ 8% vs 2022 (€ 893,850) Favourable step	€ 744,692 Bank debt 2024: € 744,692 ▼ 9% vs 2023 (€ 818,477) Favourable step	€ 662,888 Bank debt 2025: € 662,888 ▼ 11% vs 2024 (€ 744,692) Favourable step	▼ 11%
Balance sheet total	€ 1,549,809 Balance sheet total 2022: € 1,549,809 First fiscal year in the series	€ 1,599,632 Balance sheet total 2023: € 1,599,632 ▲ 3% vs 2022 (€ 1,549,809) Unchanged	€ 1,546,021 Balance sheet total 2024: € 1,546,021 ▼ 3% vs 2023 (€ 1,599,632) Unchanged	€ 1,561,400 Balance sheet total 2025: € 1,561,400 ▲ 1% vs 2024 (€ 1,546,021) Unchanged	▲ 1%
Employees (FTE)	-	-	2.7 Employees (FTE) 2024: 2.7 First fiscal year in the series	2.1 Employees (FTE) 2025: 2.1 ▼ 0.6 vs 2024 (2.7) Unchanged	▼ 0.6

Key figures of GEASSOCIEERDE APOTHEEK MARKGRAVE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to GEASSOCIEERDE APOTHEEK MARKGRAVE?

What happened at GEASSOCIEERDE APOTHEEK MARKGRAVE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 28, 2026 New annual accounts for financial year 2025: loss of € 4,387 (▼ € 49,616 vs 2024). Source: NBB ↗
2026 A. Pirlot stepped down as director. NBB
2026 J. Mannaerts stepped down as director. NBB
2020 A. Pirlot became a director. NBB
2020 J. Mannaerts became a director. NBB
Jan 1, 2008 New establishment in Antwerpen. KBO
Dec 21, 2007 Start of the company according to the CBE. KBO

In short

From € 65,962 profit in 2022 to € 4,387 loss in 2025.

Paid € 50,067 in corporate taxes since 2022.

Best year ever: 2022, with € 65,962 profit.

On average € 81,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at GEASSOCIEERDE APOTHEEK MARKGRAVE? We notify you, reason included.

Follow GEASSOCIEERDE APOTHEEK MARKGRAVE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

AFS 95.2%

APOTHEEK DE KROON 4.8%

The stake of AFS, APOTHEEK DE KROON comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

GEASSOCIEERDE APOTHEEK MARKGRAVE

G.A. Schoten 26.4%

G.A. Merelbeke 5%

G. A. Merksem 1%

AFS 1%

The shares are held by AFS (95.2%) and APOTHEEK DE KROON (4.8%). It owns 26.4% of G.A. Schoten, 5% of G.A. Merelbeke, 1% of G. A. Merksem, 1% of AFS and 0% of G.A. Plantijn itself.

See the full network in the app